The role of Amicar in same-day anterior and posterior spinal fusion for idiopathic scoliosis.

Abstract

STUDY DESIGN:

A retrospective study of the effectiveness of Amicar (epsilon aminocaproic acid).

OBJECTIVE:

Evaluate the effectiveness of Amicar in decreasing perioperative blood loss and transfusion requirements in same-day anterior (ASF) and posterior spinal fusion (PSF) with segmental spinal instrumentation (SSI) for idiopathic scoliosis.

SUMMARY OF BACKGROUND DATA:

Preliminary prospective, prospective randomized double-blind, and fibrinogen studies have demonstrated Amicar to be effective in decreasing perioperative blood loss in patients with idiopathic scoliosis undergoing PSF with SSI. Increased fibrinogen secretion is a possible explanation.

METHODS:

There were 73 consecutive patients divided into 3 study groups based on the administration of Amicar: Group 1 (n = 16), no Amicar; Group 2 (n = 18), Amicar for the PSF with SSI only; and Group 3 (n = 39), Amicar for both ASF and PSF with SSI. All patients were managed using the same general anesthesia technique, intraoperative procedure, postoperative care path, and indications for transfusion (hemoglobin <7 g/dL). Total perioperative blood loss (estimated intraoperative blood loss for both procedures and measured postoperative chest tube and PSF wound suction drainage) and total transfusion requirements between groups were compared using one-way ANOVA.

RESULTS:

There were statistically significant decreases in mean estimated intraoperative PSF with SSI, total perioperative blood loss, and transfusion requirements in the 2 Amicar groups. However, Amicar had no significant effect on estimated intraoperative ASF blood loss, chest tube drainage, or PSF wound suction drainage. Total perioperative blood loss and transfusion requirements (cell saver, autologous, directed, and allogeneic blood) were: 3442.8 +/- 1344.0 mL and 1537.1 +/- 905.1 mL in Group 1; 2089.8 +/- 684.0 mL and 485.2 +/- 349.8 mL in Group 2; and 2184.1 +/- 1163.7 mL and 531.5 +/- 510.5 mL in Group 3. There were no Amicar related complications.

CONCLUSION:

Amicar was highly effective in decreasing total perioperative blood loss and transfusion requirements in same-day ASF and PSF with SSI for idiopathic scoliosis. It results in less preoperative autologous blood donation, perioperative blood transfusion, costs, and potential transfusion-related complications. It was most effective in decreasing intraoperative estimated PSF with SSI blood loss. It had no significant effect during the ASF, postoperative chest tube, or PSF wound suction drainage. We now recommend that it be used for the PSF with SSI procedure only.

• Authors: George H Thompson, Ivan Florentino-Pineda, Connie Poe-Kochert, Douglas G Armstrong, Jochen P Son-Hing
• Journal: Spine (Spine (Phila Pa 1976)) Vol. 33 Issue 20 Pg. 2237-42 (Sep 15 2008) ISSN: 1528-1159 [Electronic] United States
• PMID: 18794767 (Publication Type: Journal Article)

Chemical References

• Antifibrinolytic Agents
• Aminocaproic Acid

Topics

• Adolescent
• Aminocaproic Acid (therapeutic use)
• Antifibrinolytic Agents (therapeutic use)
• Blood Loss, Surgical (prevention & control)
• Blood Transfusion (statistics & numerical data)
• Child
• Female
• Humans
• Male
• Postoperative Complications (prevention & control)
• Retrospective Studies
• Scoliosis (surgery)
• Spinal Fusion (adverse effects, instrumentation, methods)